FDA Recall: Baxter 70% Dextrose Injection, USP
Source: FDA
File Your Claim Now

FDA Recall: Baxter 70% Dextrose Injection, USP

Baxter • August 25, 2026

Baxter 70% Dextrose Injection Recall for Stainless-Steel Particulate Contamination

Baxter International Inc. has issued a voluntary nationwide recall of 70% Dextrose Injection, USP (2000 mL VIAFLEX plastic container) after routine testing detected stainless-steel particles in the solution. Intravenous administration of foreign particles can obstruct blood vessels and lead to life-threatening events. If you possess lot Y495066, discontinue use immediately and follow the return instructions below.

Fast Facts About the Baxter Recall

  • Company: Baxter International Inc.
  • Product Name: 70% Dextrose Injection, USP, 2000 mL VIAFLEX Plastic Container (Pharmacy Bulk Package—Not for Direct Infusion)
  • Affected Lot: Y495066
  • Product Code: 2B0296H  |  NDC: 0338-0719-06
  • Expiration: 31-Jul-2027
  • Distribution Window: 25-Jul-2026 – 28-Jul-2026
  • States Distributed: Alabama, Georgia, Tennessee
  • Reason: Possible stainless-steel particulate contamination
  • Injuries Reported: None as of 25-Aug-2026

Sources

Health Risks of Particulate-Contaminated I.V. Solutions

When particulate matter enters the bloodstream, it can:

  1. Form emboli that restrict blood flow to critical organs.
  2. Cause pulmonary embolism, stroke, or multi-organ damage.
  3. Trigger phlebitis, inflammation, or severe allergic reactions.

Because Baxter 70% Dextrose Injection is frequently used in parenteral nutrition formulas, rapid removal of the affected lot is crucial for both hospital and home-care patients.

Immediate Actions for Patients and Health-Care Providers

  • Locate the lot number on the container or shipping carton.
  • Stop using lot Y495066 without delay.
  • Quarantine remaining stock and begin the return process per facility protocol.
  • Home-infusion pharmacies should contact patients and replace any compounded admixtures made with the recalled lot.
  • Report adverse events to FDA MedWatch via the online form or by calling 1-800-332-1088.

Return & Credit Information

Baxter Healthcare Center for Service
Tel: 888-229-0001 (Mon–Fri, 7 a.m.–6 p.m. CT)

Product Images to Verify the Recall

Front label of Baxter 70% Dextrose Injection 2000 mL container
Source: FDA
Shipping carton with Baxter lot number Y495066 highlighted
Source: FDA

Frequently Asked Questions About the Baxter 70% Dextrose Injection Recall

1. Which Baxter 70% Dextrose Injection lot is under recall?
Only lot Y495066 of Baxter 70% Dextrose Injection, USP (2000 mL VIAFLEX) is affected.
2. What contamination risk prompted the Baxter 70% Dextrose Injection recall?
Testing revealed stainless-steel particles in the solution, which can lead to embolism, organ damage, or other serious complications if infused.
3. How do I confirm my product is part of the Baxter 70% Dextrose Injection recall?
Check the lot number and expiration date on the container label or shipping carton. The images above show where those identifiers are located.
4. Was Baxter 70% Dextrose Injection sold directly to consumers?
No. Distribution was limited to hospitals, health-care providers, and home-infusion pharmacies in Alabama, Georgia, and Tennessee.
5. Will Baxter provide a refund or replacement for the recalled 70% Dextrose Injection?
Yes. Contact Baxter Healthcare Center for Service at 888-229-0001 for return instructions and to arrange credit or replacement.
6. Can I continue using compounded solutions made with the recalled Baxter 70% Dextrose Injection?
No. Any parenteral nutrition admixtures prepared with lot Y495066 should be discarded and remade with an unaffected lot.
7. How do I report side effects linked to the Baxter 70% Dextrose Injection recall?
Submit a report to FDA MedWatch online or by calling 1-800-332-1088, and notify Baxter directly of any adverse events.

File Your Claim Now